Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study

Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study

Abstract Background Data on the safety and efficacy profile of tocilizumab in patients with severe COVID-19 needs to be enriched. Methods In this open label, prospective study, we evaluated clinical outcomes in consecutive patients with COVID-19 and PaO2/FiO2 < 200 receiving tocilizumab plus usua...

Full description

Bibliographic Details
Main Authors: Theodoros Karampitsakos, Elli Malakounidou, Ourania Papaioannou, Vasilina Dimakopoulou, Eirini Zarkadi, Matthaios Katsaras, Panagiota Tsiri, Georgios Tsirikos, Vasiliki Georgiopoulou, Ioanna Oikonomou, Christos Davoulos, Dimitrios Velissaris, Fotios Sampsonas, Markos Marangos, Karolina Akinosoglou, Argyris Tzouvelekis
Format: Article
Language:English
Published: BMC 2021-12-01
Series:Respiratory Research
Subjects:
COVID-19
Tocilizumab
Mortality
PaO2/FiO2
Outcomes
Online Access:https://doi.org/10.1186/s12931-021-01914-6

Internet

https://doi.org/10.1186/s12931-021-01914-6

Similar Items